Iovance Biotherapeutics Inc (NASDAQ: IOVA) is 11.07% higher on its value in year-to-date trading and has touched a low of $6.00 and a high of $18.33 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The IOVA stock was last observed hovering at around $8.47 in the last trading session, with the day’s gains setting it 0.56%.
Currently trading at $9.03, the stock is 0.68% and -7.54% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.84 million and changing 6.61% at the moment leaves the stock -15.49% off its SMA200. IOVA registered 41.54% gain for a year compared to 6-month gain of 16.07%. The firm has a 50-day simple moving average (SMA 50) of $9.767 and a 200-day simple moving average (SMA200) of $10.6857.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -25.62% loss in the last 1 month and extending the period to 3 months gives it a -8.42%, and is -3.11% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.47% over the week and 6.21% over the month.
Iovance Biotherapeutics Inc (IOVA) has around 557 employees, a market worth around $2.93B and $90.86M in sales. Profit margin for the company is -451.25%. Distance from 52-week low is 50.50% and -50.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.76%).
with sales reaching $71.57M over the same period.The EPS is expected to grow by 33.29% this year, but quarterly earnings will post 13,525.93% year-over-year. Quarterly sales are estimated to grow 14,748.60% in year-over-year returns.
Iovance Biotherapeutics Inc (IOVA) Top Institutional Holders
385.0 institutions hold shares in Iovance Biotherapeutics Inc (IOVA), with institutional investors hold 89.06% of the company’s shares. The shares outstanding are 304.62M, and float is at 246.81M with Short Float at 21.87%. Institutions hold 88.54% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 25.95 million shares valued at $208.12 million. The investor’s holdings represent 9.7478% of the IOVA Shares outstanding. As of 2024-06-30, the second largest holder is PERCEPTIVE ADVISORS LLC with 25.93 million shares valued at $207.98 million to account for 9.7412 of the shares outstanding. The other top investors are MHR FUND MANAGEMENT LLC which holds 24.0 million shares representing 9.014% and valued at over $192.46 million, while BLACKROCK INC. holds 7.9728 of the shares totaling 21.23 million with a market value of $170.23 million.
Iovance Biotherapeutics Inc (IOVA) Insider Activity
The most recent transaction is an insider sale by Maynard Ryan D, the company’s Director. SEC filings show that Maynard Ryan D sold 50,000 shares of the company’s common stock on Nov 12 ’24 at a price of $10.06 per share for a total of $0.5 million. Following the sale, the insider now owns 7500.0 shares.
Still, SEC filings show that on Feb 20 ’24, MCPEAK MERRILL A (Director) acquired 250,000 shares at an average price of $9.15 for $2.29 million. The insider now directly holds 320,150 shares of Iovance Biotherapeutics Inc (IOVA).
